Literature DB >> 9809590

Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons.

A Takashima1, T Honda, K Yasutake, G Michel, O Murayama, M Murayama, K Ishiguro, H Yamaguchi.   

Abstract

According to the amyloid hypothesis for the pathogenesis of Alzheimer's disease (AD), amyloid beta peptide (Abeta) directly affects neurons, leading to neurodegeneration and tau phosphorylation, followed by the production of paired helical filaments (PHF) in neurofibrillary tangles (NFT). To analyze the relationship between the phosphorylation sites of tau and the activation of kinases in response to Abeta, we treated cultured rat hippocampal neurons with a peptide fragment of Abeta, Abeta(25-35). Abeta(25-35) treatment activated tau protein kinase I/glycogen synthase kinase-3beta (TPKI/GSK-3beta) but not glycogen synthase kinase-3alpha (GSK-3alpha) or mitogen activated protein kinase (MAP kinase) in primary culture of hippocampal neurons. Using antibodies that recognize phosphorylated sites of tau, we showed that tau phosphorylation was enhanced in at least five sites (Ser199, Ser202, Ser396, Ser404, and Ser413 numbered according to the human tau isoform containing 441 amino acid residues), to an extent that depended on the level of TPK I/GSK-3beta. Treatment with TPK I/GSK-3beta antisense oligonucleotide inhibited the enhancement of tau phosphorylation induced by Abeta(25-35) exposure. Thus, TPK I/GSK-3beta activation by Abeta(25-35) may lead to extensive tau phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809590     DOI: 10.1016/s0168-0102(98)00061-3

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  83 in total

1.  The tangled biology of tau.

Authors:  K C Wilhelmsen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

Review 2.  Cellular models for tau filament assembly.

Authors:  Li-wen Ko; Michael DeTure; Naruhiko Sahara; Rifki Chihab; Shu-Hui Yen
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

3.  SSeCKS promote beta-amyloid-induced PC12 cells neurotoxicity by up-regulating tau phosphorylation in Alzheimer's disease.

Authors:  Zhiming Cui; Tao Tao; Chun Cheng; Junling Yang; Qin Shen; Yuhong Ji; Xiaohong Li; Haiou Liu; Aiguo Shen; Xiang Lu
Journal:  Mol Cell Biochem       Date:  2010-03-16       Impact factor: 3.396

4.  Pre-aggregated Aβ1-42 peptide increases tau aggregation and hyperphosphorylation after short-term application.

Authors:  Sabine Ott; Andreas Wolfram Henkel; Maria Kerstin Henkel; Zoran B Redzic; Johannes Kornhuber; Jens Wiltfang
Journal:  Mol Cell Biochem       Date:  2010-11-27       Impact factor: 3.396

Review 5.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

6.  The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.

Authors:  Annamaria Lanzillotta; Ilenia Sarnico; Marina Benarese; Caterina Branca; Cristina Baiguera; Birgit Hutter-Paier; Manfred Windisch; Pierfranco Spano; Bruno Pietro Imbimbo; Marina Pizzi
Journal:  J Mol Neurosci       Date:  2010-12-22       Impact factor: 3.444

7.  Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3.

Authors:  Rajakishore Mishra; Manoj K Barthwal; Gautam Sondarva; Basabi Rana; Lucas Wong; Malay Chatterjee; James R Woodgett; Ajay Rana
Journal:  J Biol Chem       Date:  2007-08-21       Impact factor: 5.157

8.  Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.

Authors:  Valentine Lahmy; Johann Meunier; Susanna Malmström; Gaelle Naert; Laurent Givalois; Seung Hyun Kim; Vanessa Villard; Alexandre Vamvakides; Tangui Maurice
Journal:  Neuropsychopharmacology       Date:  2013-03-14       Impact factor: 7.853

9.  Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.

Authors:  Charbel E-H Moussa
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

Review 10.  What can rodent models tell us about cognitive decline in Alzheimer's disease?

Authors:  Sabrina Davis; Serge Laroche
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.